Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercialising products for the treatment of central nervous system diseases, announced the issuance of a fifth patent (number 9,119,791) by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR, its novel once-daily extended-release oxcarbazepine product. The patent provides protection for the product with expiration that is no earlier than 2027.

"We are very serious about securing intellectual property protection for our innovative products. We will continue to build our patent estate to provide our products with the protection they are entitled to. We now have patent protection on Oxtellar XR and Trokendi XR through five and six issued US patents, respectively," said Jack A. Khattar, president and CEO of Supernus.

Supernus has several additional patent applications for extended-release oxcarbazepine and extended-release topiramate pending in other geographic regions.

Oxtellar XR is the first approved novel, oral, once-daily extended release formulation of oxcarbazepine for the treatment of epilepsy. Oxtellar XR is an antiepileptic drug indicated for adjunctive therapy in the treatment of partial seizures in adults and in children 6 to 17 years of age. The product is available in 150mg, 300mg, and 600mg extended-release tablets.